Stephen Smith

Title: Innovations of Stephen Smith in Biopharmaceuticals

Introduction

Stephen Smith is a notable inventor based in Newbury Park, CA (US). He has made significant contributions to the field of biopharmaceuticals, particularly in the development of bispecific antibodies. His innovative work has the potential to enhance therapeutic options for various medical conditions.

Latest Patents

Stephen Smith holds a patent for "Bispecific antibodies with cleavable C-terminal charge-paired tags." This invention is directed to a CH3-containing molecule comprising a first polypeptide with a CH3 domain and a negatively charged domain, as well as a second polypeptide with a CH3 domain and a positively charged domain. The patent outlines methods for conjugating synthetic molecules to a multi-specific antigen binding molecule, showcasing his expertise in molecular design.

Career Highlights

Stephen Smith is currently employed at Amgen Inc., a leading biotechnology company. His role at Amgen allows him to work on cutting-edge research and development projects that aim to improve patient outcomes through innovative therapies. His contributions to the field have been recognized by his peers and the scientific community.

Collaborations

Stephen has collaborated with notable colleagues, including John K Kawooya and Alex W Jacobitz. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in biopharmaceutical research.

Conclusion

Stephen Smith's work in the field of bispecific antibodies exemplifies the innovative spirit of modern biopharmaceutical research. His contributions not only advance scientific knowledge but also hold promise for future therapeutic applications.